165 related articles for article (PubMed ID: 38292518)
1. A reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder.
Mason BJ; Estey D; Roberts A; de Guglielmo G; George O; Light J; Stoolmiller M; Quello S; Skinner M; Shadan F; Begovic A; Kyle MC; Harris RA
Neurobiol Stress; 2024 Mar; 29():100604. PubMed ID: 38292518
[TBL] [Abstract][Full Text] [Related]
2. PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice.
Blednov YA; Black M; Benavidez JM; Stamatakis EE; Harris RA
Alcohol Clin Exp Res; 2016 Mar; 40(3):553-62. PubMed ID: 26857685
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate Decreases Ethanol-Induced Neuroinflammation and Oxidative Stress and Reduces Alcohol Relapse in Rats by a PPAR-α-Dependent Mechanism.
Ibáñez C; Acuña T; Quintanilla ME; Pérez-Reytor D; Morales P; Karahanian E
Antioxidants (Basel); 2023 Sep; 12(9):. PubMed ID: 37760061
[TBL] [Abstract][Full Text] [Related]
4. PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption.
Ferguson LB; Most D; Blednov YA; Harris RA
Neuropharmacology; 2014 Nov; 86():397-407. PubMed ID: 25036611
[TBL] [Abstract][Full Text] [Related]
5. Effects of peroxisome proliferator activated receptors-alpha and -gamma agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus.
Gunin AG; Bitter AD; Demakov AB; Vasilieva EN; Suslonova NV
J Endocrinol; 2004 Aug; 182(2):229-39. PubMed ID: 15283683
[TBL] [Abstract][Full Text] [Related]
6. Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.
Grover S; Kumar P; Singh K; Vikram V; Budhiraja RD
Pharmacol Biochem Behav; 2013 Oct; 111():17-23. PubMed ID: 23948071
[TBL] [Abstract][Full Text] [Related]
7. Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.
Koufany M; Jouzeau JY; Moulin D
Biomed Mater Eng; 2014; 24(1 Suppl):81-8. PubMed ID: 24928921
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence.
Matheson J; Le Foll B
Cells; 2020 May; 9(5):. PubMed ID: 32408505
[TBL] [Abstract][Full Text] [Related]
9. The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats.
Haile CN; Kosten TA
Neuropharmacology; 2017 Apr; 116():364-370. PubMed ID: 28088358
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes.
Liang F; Wang F; Zhang S; Gardner DG
Endocrinology; 2003 Sep; 144(9):4187-94. PubMed ID: 12933694
[TBL] [Abstract][Full Text] [Related]
11. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia.
Xu J; Storer PD; Chavis JA; Racke MK; Drew PD
J Neurosci Res; 2005 Aug; 81(3):403-11. PubMed ID: 15968640
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo.
Du L; Ma Y; Liu M; Yan L; Tang H
Virol J; 2017 May; 14(1):96. PubMed ID: 28545573
[TBL] [Abstract][Full Text] [Related]
13. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
Bisgaier CL; Oniciu DC; Srivastava RAK
J Cardiovasc Pharmacol; 2018 Jul; 72(1):3-10. PubMed ID: 29621036
[TBL] [Abstract][Full Text] [Related]
14. Underlying mechanisms of pharmacology and toxicity of a novel PPAR agonist revealed using rodent and canine hepatocytes.
Guo Y; Jolly RA; Halstead BW; Baker TK; Stutz JP; Huffman M; Calley JN; West A; Gao H; Searfoss GH; Li S; Irizarry AR; Qian HR; Stevens JL; Ryan TP
Toxicol Sci; 2007 Apr; 96(2):294-309. PubMed ID: 17255113
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate reduces amyloidogenic processing of APP in APP/PS1 transgenic mice via PPAR-α/PI3-K pathway.
Zhang H; Gao Y; Qiao PF; Zhao FL; Yan Y
Int J Dev Neurosci; 2014 Nov; 38():223-31. PubMed ID: 25447788
[TBL] [Abstract][Full Text] [Related]
16. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.
Oliveira AC; Bertollo CM; Rocha LT; Nascimento EB; Costa KA; Coelho MM
Eur J Pharmacol; 2007 Apr; 561(1-3):194-201. PubMed ID: 17343847
[TBL] [Abstract][Full Text] [Related]
17. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis.
Okamoto H; Iwamoto T; Kotake S; Momohara S; Yamanaka H; Kamatani N
Clin Exp Rheumatol; 2005; 23(3):323-30. PubMed ID: 15971419
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
Srivastava RA
Atherosclerosis; 2011 Jan; 214(1):86-93. PubMed ID: 21093860
[TBL] [Abstract][Full Text] [Related]
20. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
